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The mainstay of current therapies for osteoporosis is
antiresorptive agents such as calcium, vitamin D,
oestrogen, selective oestrogen receptor modulators
(SERMs), calcitonin and the bisphosphonates. These
drugs reduce but do not eliminate fracture risk, and do
not restore lost bone structure. Anabolic agents have the
potential to increase bone mineral density (BMD), restore
skeletal micro-architecture and reduce fracture risk to a
greater extent than the antiresorptives. Fluoride was the
first anabolic agent to be used in the treatment of
osteoporosis, followed by growth hormone and insulin-like
growth factor. More recently, strontium, statins and
parathyroid hormone (PTH) have been added to the list,
with recombinant human PTH emerging as the most
promising osteo-anabolic agent to date.1
Intermittent, low-dose PTH administration causes rapid
stimulation of bone formation resulting in a marked
increase in bone mass, size and strength, as well as
improvements in trabecular micro-architecture (e.g. an
increase in trabecular number, decrease in trabecular
spacing and major improvements in histological indices of
trabecular connectivity) and cortical geometry (e.g. an
increase in cortical thickness, cross-sectional area and
strength, despite a transient increase in endocortical
porosity).2-10 Following a number of smaller studies on the
effects of PTH on fracture risk, the results of a large
randomised placebo-controlled trial involving 1 637
women with postmenopausal osteoporosis were recently
published.11 Compared with placebo, daily subcutaneous
injection of hPTH (1-34), for as little as 21 months, reduced
the risk of new vertebral fractures by 65 - 70% and non-
vertebral fractures by 35 - 40%. Favourable results on the
effects of PTH on bone mass (BMD) and bio-markers of
bone turnover have also been reported in male12-14 and
glucocorticoid-induced15 osteoporosis.
Because PTH increases both bone formation and bone
resorption, it was initially postulated that combining PTH
with an antiresorptive agent would enhance its effect on 
bone mass and strength. Controlled, comparative studies
to test this hypothesis are limited and confined to BMD
and biomarker data. Whereas concomitant treatment with
oestrogen (or a SERM) plus PTH does not appear to alter
outcome,4,15 the concurrent use of PTH and a more potent
antiresorptive agent like alendronate has recently been
shown to reduce the anabolic effects of PTH on BMD and
biochemical markers of bone formation in both men14 and
women16 with osteoporosis. Biomarkers of bone resorption
increased in patients treated with PTH alone, and
decreased in those treated with PTH plus alendronate.
Longer-term studies employing fracture rate as primary
endpoint are required to determine whether and how
antiresorptive drugs can be used in conjunction with
PTH. Limited data are also available on the skeletal
response following discontinuation of PTH treatment.
While some studies have suggested that BMD is
maintained, others have shown that BMD decreases after
PTH therapy is stopped.17,18 Further studies are required to
clarify this issue.
Side-effects of PTH have been limited to occasional
nausea, headaches and leg cramps. Mild hypercalcaemia
occurs in some 10% of patients receiving 20 µg PTH daily,
but the incidence of hypercalciuria and renal stone
disease does not appear to increase.11 Serum uric acid
levels may increase by up to 20%, but clinical gout has not
been shown to be more prevalent in patients treated with
PTH. Of some concern too is the tumorigenic potential of
PTH. Long-term studies with high-dose PTH,
administered to 6-week-old Fisher 344 rats, have
demonstrated a dose-related increased risk of osteogenic
sarcoma.19,20 This effect is consistent with lifelong
exposure, in a growing rodent, to high-dose PTH and is
unlikely to have relevance to human bone physiology.
Shorter or lower-dose exposure to PTH has not resulted in
the development of osteosarcomas or other bone tumours.
All primate studies have failed to show a similar
association and osteogenic sarcomas do not occur with
increased frequency in patients with primary
hyperparathyroidism, nor were they noted in any of the
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PTH (1-34) for up to 3 years.19-22 It is, therefore, reasonable
to conclude that PTH is safe in human subjects, although
ongoing safety data need to be collated.
The need for a position paper on
the use of PTH
PTH (1-34) or teriparatide will soon become available as a
treatment option for osteoporosis in South Africa. The
local cost of this product will undoubtedly be high
(estimated at R50 000 per annum) and poses serious
ethical dilemmas with regard to the allocation of
expensive resources. Clear indications for its use, close
audit of its appropriate and cost-effective utilisation and
every effort to make this valuable drug available to all,
have determined the need for this position paper, the
methodology of which is delineated in Annexure A.
Indications for the use of PTH 
(1-34)
Whereas many potential indications for its use may exist
(e.g. very low prevalent BMD, high fracture risk), we
recommend that PTH (1-34) should only be used in
patients with severe, established osteoporosis, i.e.:
1. A low BMD and two or more prevalent fractures, or
2. Failed antiresorptive therapy, i.e. after adhering to
adequate antiresorptive therapy for 12 months or more,
the patient experiences: (i) an incident fragility fracture; or
(ii) unacceptable rate of bone loss (e.g. a decrease in
vertebral BMD of ≥ 5% per annum) as documented on two
or more consecutive follow-up BMD measurements.
Contraindications to the use of 
PTH (1-34)
The following are recommended absolute and relative
contra-indications to the use of PTH:
Absolute
• Growing individuals (age < 25 years)
• Pregnancy and lactation
• Pre-existing hypercalcaemia
• Renal impairment (serum creatinine > 180 mmol/l)
• Marked increase (≥ 3 ) in liver enzymes
• Neoplasm(s) in the previous 5 years
• Increased risk of osteosarcoma (e.g. prior skeletal
radiation; Paget’s disease of bone).
Relative
• Mild renal insufficiency (serum creatinine 120 - 180
mmol/l)
• Moderate increase (< 2 ) in liver enzymes
• Possible osteomalacia
• Previous kidney stones
• Gout.
Dose and duration of PTH (1-34)
therapy
We recommend that 20 µg PTH (1-34) per day should be
used, for no longer than 18 months.
Patient selection, treatment and
follow-up protocols
• Only patients subjected to a full clinical and laboratory
work-up will be considered for treatment with PTH (1-
34). Details of said assessment are depicted in
Annexure B, but aim to confirm a diagnosis of
osteoporosis and to rule out other causes of a low BMD
(e.g. osteomalacia, primary hyperparathyroidism), rule
out causes of secondary osteoporosis which may
require treatment in their own right, evaluate the
severity of the disease, and assess compliance and
adherence to prior therapy for osteoporosis.
• Each application for PTH (1-34) treatment will be
assessed by a working group consisting of senior
council members of the National Osteoporosis
Foundation of South Africa (NOFSA). These NOFSA
councillors will be blinded to the identity of the primary
care physician and will not be remunerated in any way
for services rendered. A National Registry of patients
treated with teriparatide will be established. Only
patients who comply with the recommended
indications for PTH (1-34) treatment will be considered.
If clinical or biochemical assessment (increased
biomarkers of bone turnover in the absence of a fracture
in the preceding 3 months) suggest poor adherence to
antiresorptive therapy, improved compliance will be
required before treatment with PTH (1-34) is
considered.
• Enrolled patients will receive daily supplements of 500
mg of elemental calcium and 400 - 800 IU of vitamin D.
Given reports that concurrent use of PTH and
alendronate may ameliorate the anabolic effects of
PTH,14,16 concomitant treatment with PTH plus
antiresorptive agents is not recommended. If patients
were previously treated with bisphosphonates these
agents should therefore be discontinued before
initiation of PTH therapy. A washout period, without
active treatment, is not however deemed necessary in
these patients, given the severity of their disease.
• Careful clinical follow-up of all subjects is required (see
National Registry above). Serum and urine (24-hour)
calcium levels should be monitored at 1, 6 and 12
months after starting PTH therapy. Assessment of
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vertebral morphometry employing standard spine X-
rays, should be obtained at 9 and 18 months. The
standard post-launch osteosarcoma surveillance
programme, initiated and funded by the manufacturer
(Eli Lilly), is mandatory for all patients.
• Following completion of the 18-month course of PTH 
(1-34) therapy, treatment with a potent antiresorptive
agent (e.g. bisphosphonate) is recommended, to
preserve bone mass gained.
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Annexure A: Methodology
The National Osteoporosis Foundation (NOFSA) was
approached by the manufacturer of teriparatide (Eli Lilly)
to establish appropriate and cost-effective indications and
treatment protocols for the use of this agent in the
management of patients with osteoporosis.
A Working Group consisting of 6 senior Council Members
of NOFSA was established. Following three meetings of
the Working Group and the development of a draft
position paper, a final document was electronically
circulated to the entire Council of NOFSA. Amendments
to this document were made where there was sufficient
need in accordance with the comments received. The
manufacturer was not involved in the establishment,
content or funding of the position paper in any way. Once
finalised, the position paper was sent for publication to
the South African Medical Journal. The paper will also be
available on the NOFSA web site
(www.osteoporosis.org.za).
Annexure B: Patient assessment
Before initiating treatment with PTH (1-34)/teriparatide, a
pro forma form containing the following clinical and
laboratory data is to be completed so as to enable the
Working Group to assess the application:
• History, physical examination and urinalysis (including
risk factor assessment for osteoporosis and falls, fracture
history, nature of and adherence to current therapy)
• BMD measurement of the spine and hip (DEXA)
• X-rays of the thoraco-lumbar spine (antero-posterior and
lateral)
• Serum calcium, albumin, phosphate and total alkaline
phosphatase
• Full blood count and sedimentation rate
• Serum protein electrophoresis
• Serum creatinine and uric acid
• Urine calcium and creatinine (24-hour urine collection)
• Serum gonadotrophins (LH, FSH), and testosterone
(men) or oestradial (women in whom menopausal state
is uncertain)
• Serum ALT, AST, GGT and bilirubin
• Serum osteocalcin and urine deoxypyridinoline (or
equivalent biomarkers of bone turnover) to assess
efficacy of antiresorptive therapy — unless the patient
is not receiving any active treatment or has sustained a
fracture in the preceding 3 months (known to increase
biomarker levels).
For further information on the clinical, densitometric and
laboratory assessment of patients with osteoporosis, the
reader is referred to the SAMA Osteoporosis Clinical
Guideline, S Afr Med J 2000, 90: 905-944.
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